Loading...

FITC anti-mouse Ly-6G/Ly-6C (Gr-1) Antibody

Pricing & Availability
Clone
RB6-8C5 (See other available formats)
Regulatory Status
RUO
Other Names
Gr-1
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
rb6-8c5
C57BL/6 mouse bone marrow stained with Ly-6G/Ly-6C (clone RB6-8C5) FITC and CD11b PE.
  • rb6-8c5
    C57BL/6 mouse bone marrow stained with Ly-6G/Ly-6C (clone RB6-8C5) FITC and CD11b PE.
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
108405 50 µg 20€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
108406 500 µg 102€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Gr-1 is a 21-25 kD protein also known as Ly-6G/Ly-6C. This myeloid differentiation antigen is a glycosylphosphatidylinositol (GPI)-linked protein expressed on granulocytes and macrophages. In bone marrow, the expression levels of Gr-1 directly correlate with granulocyte differentiation and maturation; Gr-1 is also transiently expressed on bone marrow cells in the monocyte lineage. Immature Myeloid Gr-1+ cells play a role in the development of antitumor immunity.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Raised against granulocytes of mouse origin
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C19. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A819. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.420.

The RB6-8C5 antibody has been used to identify peripheral blood neutrophils and deplete granulocytes in vivo. Additional reported applications (for relevant formats of this clone) include: in vitro complement-mediated cytotoxicity2, in vivo depletion3-5,9, immunoprecipitation1, immunohistochemical staining6 (including paraffin-embedded sections9,16,33-35, acetone-fixed frozen sections11 and zinc-fixed sections15), and Western blotting7. RB6-8C5 is not suitable for depletion of hepatic myeloid derived suppressor cells (MDSCs)20.

Special Note: For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 108436).

Application References
  1. Fleming TJ, et al. 1993. J. Immunol. 151:2399. (IP)
  2. Brummer E, et al. 1984. J. Leukocyte Biol. 36:505. (CMCD)
  3. Stoppacciaro A, et al. 1993. J. Exp. Med. 178:151. (Deplete)
  4. Tumpey TM, et al. 1996. J. Virol. 70:898. (Deplete)
  5. Czuprynski CJ, et al. 1994. J. Immunol. 152:1836. (Deplete)
  6. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  7. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819. (WB)
  8. Engwerda CR, et al. 2004. Am. J. Pathol. 165:2123.
  9. Brown CR, et al. 2004. Infect. Immun. 72:4956. (Deplete, IHC)
  10. Andoniou CE, et al. 2005. Nature Immunology 6:1011. (FC) PubMed
  11. Li M, et al. 2006. P. Natl. Acad. Sci USA 103:11736. (IHC)
  12. Dzhagalov I, et al. 2007. Blood 109:1620. (FC) PubMed
  13. Fazilleau N, et al. 2007. Nature Immunol. 8:753. (FC) PubMed
  14. Heuser M, et al. 2007. Blood 110:1639. (FC) PubMed
  15. Wang T, et al. 2007. Infect. Immun. 75:1144. (IHC)
  16. Bosio CM, et al. 2007. J. Immunol. 178:4538. (IHC)
  17. Boehme SA, et al. 2009. Int. Immunol. 21:81. (IHC)
  18. Piao Y, et al. 2012. Neuro Oncol. 14:1379. PubMed
  19. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
  20. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
  21. Li J, et al. 2012. Arthritis Rheum. 64:1098. PubMed
  22. Fan Q, et al. 2014. Cancer Res. 74:471. PubMed
  23. Korrer MJ, et al. 2014. PLoS One. 9:91370. PubMed
  24. Morshed M, et al. 2014. J Immunol. 192:5314. PubMed
  25. Collins C, et al. 2014. PNAS. 111:9899. PubMed
  26. Madireddi S, et al. 2014. J Exp Med. 211:1433. PubMed
  27. Bianchi G, et al. 2014. Cell Death Dis. 5:1135. PubMed
  28. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
  29. Roderick JE, et al. 2014. PNAS. 111:14436. PubMed
  30. Distel E, et al. 2014. Circ Res. 115:759. PubMed
  31. Iwai H, et al. 2015. Tuberculosis. 95:246. PubMed
  32. Charmsaz S, et al. 2015. PLoS One. 10:130692. PubMed
  33. Whiteland J, et al. 1994 J Histochem Cytochem 43:3 (IHC-P)
  34. Brown C, et al. 2003 J Immunology 171:2 (IHC-P)
  35. Obregon-Henao A, et al. PLoS One 8:11 (IHC-P)
Product Citations
  1. Zhang J, et al. 2015. PLoS One. 10:130441. PubMed
  2. Montagner S, et al. 2016. Cell Rep. 15: 1566-1579. PubMed
  3. D'Alessandro G, et al. 2020. Eur J Immunol. 50:705. PubMed
  4. Chang YS, et al. 2020. Int J Mol Sci. 21:00. PubMed
  5. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
  6. Furuhashi K, et al. 2017. Immunology. 151:227. PubMed
  7. Petrova T, et al. 2020. Sci Rep. 10:3479. PubMed
  8. Shah D, et al. 2021. Oncoimmunology. 10:1939601. PubMed
  9. Bruggemann TR, et al. 2022. iScience. 25:105185. PubMed
  10. Kim JS, et al. 2020. Immunity. 54(1):176-190.e7. PubMed
  11. Guan F, et al. 2017. J Hematol Oncol. 10.1186/s13045-017-0446-7. PubMed
  12. Kitur K, et al. 2016. Cell Rep. 16:2219-2230. PubMed
  13. Gazit R, et al. 2014. J Exp Med. 211:1315. PubMed
  14. Jackson A, et al. 2014. J Leukoc Biol. 92:609. PubMed
  15. Jones NM, et al. 2019. BMC Cancer. 1.127777778. PubMed
  16. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  17. Gan C, et al. 2022. Respir Res. 23:32. PubMed
  18. Morimura S, et al. 2013. Am J Pathol. 182:6140. PubMed
  19. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  20. Zhang Z, et al. 2020. J Immunol. 204:3400. PubMed
  21. Turner JA, et al. 2020. Immunity. 53:1202. PubMed
  22. Chen X, et al. 2021. Theranostics. 11:4655. PubMed
  23. Hirano KI, et al. 2021. eLife. 0.416666666666667. PubMed
  24. Wang X, et al. 2016. PLoS Pathog. 12: 1005367. PubMed
  25. Bowers E, et al. 2018. Nat Med. 24:95. PubMed
  26. Al-Rifai R, et al. 2022. Nat Commun. 13:6592. PubMed
  27. Ma C, et al. 2022. Proc Natl Acad Sci U S A. 119:. PubMed
  28. Nagatake T, et al. 2022. Mucosal Immunol. 15:289. PubMed
  29. Tilstam PV, et al. 2021. J Clin Invest. 131:. PubMed
  30. Martin R, et al. 2014. J Leukoc Biol. 96:151. PubMed
  31. Jin X, et al. 2019. Mol Cell. 73:22:00. PubMed
  32. Antonia O Cuff et al. 2017. Wellcome open research. 2:39 . PubMed
  33. Karachi A, et al. 2019. Neuro Oncol. 1.381944444. PubMed
  34. Joseph R, et al. 2021. Br J Cancer. 125:176. PubMed
  35. Zong L, et al. 2021. NPJ Aging Mech Dis. 7:25. PubMed
  36. Herman KD, et al. 2022. Front Immunol. 13:956991. PubMed
  37. Blijswijk J, et al. 2015. J Immunol. 194:307. PubMed
  38. Cuff AO, et al. 2020. Frontiers in Immunology. 1.930555556. PubMed
  39. Cao W, et al. 2017. Immunity. 47:1182. PubMed
  40. Wang C, et al. 2017. J Immunol. 10.4049/jimmunol.1700671. PubMed
  41. Uchida A, et al. 2021. J Inflamm Res. 14:3089. PubMed
  42. Pawaria S, et al. 2020. Arthritis Rheumatol. 72:359. PubMed
  43. Zhang Z, et al. 2021. Oncoimmunology. 10:1912472. PubMed
  44. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
  45. Fang R, et al. 2019. Mucosal Immunol. 12:1092. PubMed
  46. Piao W, et al. 2020. Cell Reports. 30(4):1052-1062.e5.. PubMed
  47. Qi X, et al. 2019. Nat Med. 25:1225. PubMed
  48. Geng T, et al. 2022. Methods Mol Biol. 2585:71. PubMed
  49. Suo J, et al. 2014. J Leukoc Biol. 96:133. PubMed
  50. Park HB, et al. 2020. Oncoimmunology. 9:1772663. PubMed
  51. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  52. Gu Y, et al. 2021. Cell Res. Online ahead of print. PubMed
  53. Kakizaki M, et al. 2021. Cell Death Dis. 12:1010. PubMed
  54. Jaworska K, et al. 2015. J Immunol. 194:325. PubMed
  55. Shankar J 2016. Innate Immunity. 22: 31 - 39. PubMed
  56. Lu X, et al. 2016. Nat Commun. 7: 12719. PubMed
  57. Li Y, et al. 2020. Cell Stem Cell. 27(5):732-747.e7. PubMed
  58. Omori S, et al. 2021. Cell Reports. 34(6):108734. PubMed
  59. Derecka M, et al. 2020. Nat Immunol. 261:21. PubMed
  60. Morimura S, et al. 2021. Int J Mol Sci. :22. PubMed
  61. Greenwald AC, et al. 2019. J Exp Med. 216:215. PubMed
  62. Codina A, et al. 2019. Cell Syst. 8:136. PubMed
  63. Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed
  64. Dong S, et al. 2021. Nature. 591:117. PubMed
  65. Nguyen GT, et al. 2021. iScience. 24(8):102871. PubMed
  66. Harb H, et al. 2021. Immunity. 54(6):1186-1199.e7. PubMed
  67. Tartey S, et al. 2021. Cancer Research. 81(9):2358-2372. PubMed
  68. Siamishi I, et al. 2020. Cell Reports. 31(11):107756. PubMed
  69. Reismann D, et al. 2017. Nat Commun.. 10.1038/s41467-017-01538-9. PubMed
  70. Wang H, et al. 2022. J Nanobiotechnology. 20:445. PubMed
  71. Shen X, et al. 2021. Front Immunol. 12:710750. PubMed
  72. Kren N, et al. 2020. Sci Rep. 10:7390. PubMed
  73. Bei T, et al. 2021. Molecules. 26:. PubMed
  74. Coquery C, et al. 2014. PLoS One. 9:102284. PubMed
  75. Kruta M, et al. 2021. Cell Stem Cell. :. PubMed
  76. Xiang W, et al. 2018. Nat Commun. 9:2574. PubMed
  77. Casulli J, et al. 2019. Nat Commun. 10:2121. PubMed
  78. Wara AK, et al. 2020. Cell Rep. 33:108550. PubMed
  79. Liu B, et al. 2022. Mol Med Rep. 26:. PubMed
  80. Li X, et al. 2020. Nat Commun. 4.877777778. PubMed
  81. Uderhardt S, et al. 2019. Cell. 177:541. PubMed
  82. Wang Q, et al. 2018. Int J Biol Sci. 14:147. PubMed
  83. Zhai K, et al. 2021. Nat Cancer. 2:1136. PubMed
  84. Rashid MH, et al. 2021. Oncol Rep. 45:1171. PubMed
  85. Yamada D, et al. 2014. J Immunol. 192:4112. PubMed
  86. Ish-Shalom E, et al. 2016. J Immunol. 196: 156 - 167. PubMed
  87. Xi‐Zhi J Guo et al. 2018. Immunity. 49(3):531-544 . PubMed
  88. Robinett RA et al. 2018. Cell systems. 7(1):41-48 . PubMed
  89. Nowlan B, et al. 2019. Haematologica. 105:71. PubMed
  90. Zhang W, et al. 2020. Nat Commun. 11:1187. PubMed
  91. Daemen S, et al. 2021. STAR Protoc. 2:100511. PubMed
  92. Ali S, et al. 2021. PLoS One. 16:e0246646. PubMed
  93. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  94. Rosenbaum SR, et al. 2020. Cell Rep. 30:510. PubMed
  95. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  96. Baomei Wang et al. 2019. Cell reports. 26(6):1614-1626 . PubMed
  97. Kitur K, et al. 2015. PLoS Pathog. 11:1004820. PubMed
  98. Chen Z, et al. 2016. PLoS One. 11: 0146681. PubMed
  99. Tuong ZK, et al. 2021. Cell Rep. 37:110132. PubMed
  100. Harb H, et al. 2020. Nat Immunol. 1359:21. PubMed
  101. Chen C, et al. 2020. Cell Rep. 2136:30. PubMed
  102. Zhao N, et al. 2018. J Clin Invest. 26:84. PubMed
  103. Avalle L, et al. 2020. Mol Ther Methods Clin Dev. 0.793055556. PubMed
  104. Golan K et al. 2018. Cell stem cell. 23(4):572-585 . PubMed
  105. Zegarra‐Ruiz DF et al. 2018. Cell host & microbe. 25(1):113-127 . PubMed
  106. DiMenna L, et al. 2010. J Immunol. 184:5475. PubMed
  107. Magee JA, et al. 2021. Stem Cell Reports. 16:20. PubMed
  108. Mesa-Nuñez C, et al. 2022. Mol Ther Methods Clin Dev. 26:459. PubMed
  109. Maulhardt HA, et al. 2020. Invest New Drugs. 1618:38. PubMed
  110. Gao P, et al. 2020. Front Immunol. 1.636111111. PubMed
  111. Iwanami N, et al. 2020. iScience. 23:101260. PubMed
  112. Chauhan P, et al. 2014. Int Immunopharmacol. 21:63. PubMed
  113. Li K, et al. 2020. Nat Commun. 0.795138889. PubMed
  114. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
  115. Burton OT, et al. 2018. Clin Exp Allergy. 48:288. PubMed
  116. Luo H, et al. 2019. Cell Rep. 26:945. PubMed
  117. Goldberg EL, et al. 2021. Cell Metabolism. :. PubMed
  118. Saul S, et al. 2019. J Leukoc Biol. N/A. PubMed
  119. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  120. Krotova K, et al. 2019. Mol Ther Oncolytics. 15:166. PubMed
  121. Lai NY, et al. 2020. Cell. 180:33:00. PubMed
  122. Maicas N, et al. 2017. PLoS One. 12(2):e0168981. PubMed
  123. An J, et al. 2015. Biochem Biophys Res Commun. 461:142. PubMed
  124. Morales J, et al. 2014. J Leukoc Biol. 95:643. PubMed
  125. Sethuraman SN, et al. 2020. Theranostics. 10:3397. PubMed
  126. Gu Z, et al. 2021. Nat Genet. 53:672. PubMed
  127. Qu J, et al. 2021. Int J Biol Sci. 17:2756. PubMed
RRID
AB_313370 (BioLegend Cat. No. 108405)
AB_313371 (BioLegend Cat. No. 108406)

Antigen Details

Structure
21-25 kD
Distribution

Granulocytes, monocytes

Cell Type
Granulocytes, Monocytes, Neutrophils
Biology Area
Immunology, Innate Immunity
Antigen References

1. Fleming TJ, et al. 1993. J. Immunol. 151:2399.
2. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819.
3. Goni O, et al. 2002. Int. Immunol. 14:1125.

Gene ID
17067 View all products for this Gene ID 546644 View all products for this Gene ID
UniProt
View information about Ly-6G Ly-6C on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All Ly-6G/Ly-6C Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Biotin anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IHC,IP,WB
FITC anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PE anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PE/Cyanine5 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Purified anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IHC,IP,WB
PE/Cyanine7 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Alexa Fluor® 488 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IHC
Alexa Fluor® 647 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,SB
Alexa Fluor® 700 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 711™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
APC/Cyanine7 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Pacific Blue™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PerCP/Cyanine5.5 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PerCP anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 421™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 570™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Ultra-LEAF™ Purified anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IP,CMCD,Depletion,IHC,WB
Brilliant Violet 510™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 605™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 650™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Alexa Fluor® 594 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 IHC-F,FC
Purified anti-mouse Ly-6G/Ly-6C (Gr-1) (Maxpar® Ready) RB6-8C5 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
APC/Fire™ 750 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
TotalSeq™-A0116 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 PG
TotalSeq™-C0116 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 PG
TotalSeq™-B0116 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 PG
Spark Blue™ 550 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
APC/Fire™ 810 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Spark Violet™ 423 anti-mouse Ly-6G/Ly-6C (GR-1) Antibody RB6-8C5 FC
Spark UV™ 387 anti-mouse Ly-6G/Ly-6C (GR-1) RB6-8C5 FC
Spark Violet™ 538 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Go To Top Version: 2    Revision Date: 12-09-2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account